Sustained beneficial effect of a therapy with the HMG-Co-A-reductase inhibitor fluvastatin on endothelial function in renal transplant recipients;Einfluβ der therapie mit dem HMG-CoA-reduktaseinhibitor fluvastatin auf endothelfunktion und arterielle distensibilität großer arterien bei patienten nach nierentransplantation

Nieren- und Hochdruckkrankheiten

Volumn 33, Issue 10, 2004, Pages 577-583

  Kosch, M ^a   Barenbrock, M ^a   Hausberg, M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Arterial distensibility; Cholesterol; Endothelial function; Fluvastatin; HMG CoA reductase inhibitor; Renal transplantation

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTERY COMPLIANCE; ARTERY WALL; ARTICLE; BRACHIAL ARTERY; CAROTID ARTERY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY TRANSPLANTATION; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RISK BENEFIT ANALYSIS; VASODILATATION;

EID: 8744253306     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: 10.5414/nhp33577     Document Type: Article

References (23)

1. Barenbrock M., M. Hausberg, M. Kosch, K. Kisters, A.P.G. Hoeks, K.H. Rahn: Effects of hyperparathyroidism on arterial distensibility in renal transplant recipients. Kidney Int. 54, 210-215 (1998).
2. Barenbrock M., M. Kosch, E. Jöster, K. Kisters, K.H. Rahn, M. Hausberg: Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J. Hypertens. 20, 79-84 (2002).
3. Blacher J., A.P. Guerin, B. Pannier, S.J. Marchais, M.E. Safar, G.M. London: Impact of aortic stiffnes on survival in end-stage renal disease. Circulation 99, 2434-2439 (1999).
4. Giannattasio C., A.A. Mangoni, M. Failla et al.: Impaired radial artery compliance in normotensi ve subjects with familial hypercholesterolemia. Atherosclerosis 124, 249-260 (1996).
5. Goldberg I.J.: Lipoprotein metabolism in normal and uremic patients. Am. J. Kidney Dis. 21, 87-90 (1993).
6. Hausberg M., M. Kosch, F. Stam et al.: Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int. 59, 1473-1479 (2001).
7. Hausberg M., K. Kisters, M. Kosch, K.H. Rahn, M. Barenbrock: Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int. 55, 1104-1110 (1999).
8. Hoeks A.P.G., P.J. Brands, F.A. Smeets, R.S. Reneman: Assessment of distensibility of superficial arteries. Ultrasound Med. Biol. 16, 121-128 (1990).
9. Holdaas H., A.G. Jardine, D.C. Wheeler et al.: Effect of fluvastatin on acute renal allograft rejections: a randomized multicenter trial. Kidney Int. 60, 1990-1997 (2001).
10. Jarvisalo M.J., J.O. Toikka, T. Vasankari et al.: HMG-CoA reductase inhibitors are related to im proved systemic endothelial function in coronary artery disease. Atherosclerosis 147, 237-242 (1999).
11. Keane W.F.: Metabolic pathogenesis of cardiorenal disease. Am. J. Kidney Dis. 38, 1372-1375 (2001).
12. Keane W.F., B.M. Brenner, A. Mazzu, A. Agro: The CHORUS (cerivastin in heart outcomes in renal disease: understanding survival) protocol: a double-blind, placebo-controlled trial in patients with ESRD. Am. J. Kidney Dis. 37, S48-53 (2001).
13. Kosch M., M. Barenbrock, B. Suwelack, K.H. Rahn, M. Hausberg: Effect of a 3-year HMG-CoA inhibitor therapy on endothelial function and distensibility of large arteries in hypercholesterinemic renal transplant recipient. Am. J. Kidney Dis. 41, 1088-1096 (2003).
14. Laufs V., V. La Fata, J. Plutzky, J.K. Liao: Up-regulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97, 1129-1135(1998).
15. London G.M., T.B. Drüeke: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 51, 1678-1695 (1997).
16. London G.M., B. Pannier, M. Agharazii, A.P. Guerin, F.H. Verbeke, S.J. Marchais: Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int. 65, 700-704 (2004).
17. O'Briscoll G., D. Green, R.R. Taylor: Simvastatin, a HMG coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95, 1126-1131 (1997).
18. Pannier B., A.P. Guerin, S.J. Marchais, S.J. Metivier, M.E. Safar, G.M. London: Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int. 57, 1091-1093 (2000).
19. Reneman R.S., T. van Merode, P. Hick et al.: Cardiovascular applications of multigate-pulsed Doppler systems. Ultrasound Med. Biol. 12, 357-370 (1986).
20. Vogel R.A., M. C. Corretti, G.D. Plotnick: Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am. J. Cardiol. 77, 37-40 (1996).
21. Wilkinson I.B., A. Qasem, CM. McEniry, D.J. Webb, A.P. Avolio, J.R. Cockcroft: Nitric oxide regulates local arterial distensibility in vivo. Circulation 105, 213-217 (2002).
22. Shige H., A. Dart, P. Nestel: Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 155, 245-250 (2001).
23. Smilde T.J., F.W. van den Berkmortel, H. Wollersheim, H. van Langen, J.J. Kastelein, A.F.H. Stalenhoef: The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolemia. Eur. J. Clin. Invest. 30, 473-480 (2000).